Achieving the Ideal Balance Between Safety and Efficacy: What Does Subgroup Analysis of Patients in ENGAGE-AF Trial Teach Us About NOAC Use in Elderly Patients? In Patients with Heart Failure? In Patients with Low GFR? In Patients on ASA or Antiplatelet Therapy?

Achieving the Ideal Balance Between Safety and Efficacy: What Does Subgroup Analysis of Patients in ENGAGE-AF Trial Teach Us About NOAC Use in Elderly Patients? In Patients with Heart Failure? In Patients with Low GFR? In Patients on ASA or Antiplatelet Therapy?


Published

January 29, 2018

Created by

CMEducation Resources symposium